Skip to main content

Advertisement

SpringerLink
Log in

Ten years of progress in vaccination against cancer: the need to counteract cancer evasion by dual targeting in future therapies

  • Focussed Research Review
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Abstract

Although cancer immunology has made vigorous progress over the last decade, its future remains uncertain. Tumors have clearly proved subject to immune surveillance, leading to antigenic editing, and means of activating both T and B arms of the immune system have been devised. Therapeutic vaccination and monoclonal antibody therapy have so far proved disappointing, because tumors prove adept at evasion from immune control. Dual targeting could well counteract evasion, provided that the two targets are independent and are attacked simultaneously. This stage has nearly but not quite been reached in several forms of immunotherapy, particularly of B-cell cancers, although such treatment also carries hazards.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD (2001) IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410:1107–1111

    Article  PubMed  CAS  Google Scholar 

  2. Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, Smyth MJ, Schreiber RD (2007) Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450:903–907

    Article  PubMed  CAS  Google Scholar 

  3. Copier J, Dalgleish AG, Britten CM, Finke LH, Gaudernack G, Gnjatic S, Kallen K, Kiessling R, Schuessler-Lenz M, Singh H, Talmadge J, Zwierzina H, Hakansson L (2009) Improving the efficacy of cancer immunotherapy. Eur J Cancer 45:1424–1431

    Article  PubMed  CAS  Google Scholar 

  4. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM (2007) Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 370:59–67

    Article  PubMed  Google Scholar 

  5. Heusinkveld M, Welters MJ, van Poelgeest MI, van der Hulst JM, Melief CJ, Fleuren GJ, Kenter GG, van der Burg SH (2010) The detection of circulating Human Papillomavirus (HPV)-specific T cells is associated with improved survival of patients with deeply infiltrating tumors. Int J Cancer

  6. Mammas IN, Sourvinos G, Zaravinos A, Spandidos DA (2010) Vaccination against human papilloma virus (HPV): epidemiological evidence of HPV in non-genital cancers. Pathol Oncol Res

  7. Prehn RT, Main JM (1957) Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst 18:769–778

    PubMed  CAS  Google Scholar 

  8. Fassati A, Mitchison NA (2009) Testing the theory of immune selection in cancers that break the rules of transplantation. Cancer Immunol Immunother 59:643–651

    Article  PubMed  Google Scholar 

  9. Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P (2006) Human T cell responses against melanoma. Annu Rev Immunol 24:175–208

    Article  PubMed  CAS  Google Scholar 

  10. Speiser DE, Pittet MJ, Rimoldi D, Guillaume P, Luescher IF, Lienard D, Lejeune F, Cerottini JC, Romero P (2003) Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells. Semin Cancer Biol 13:461–472

    Article  PubMed  CAS  Google Scholar 

  11. Carretero R, Romero JM, Ruiz-Cabello F, Maleno I, Rodriguez F, Camacho FM, Real LM, Garrido F, Cabrera T (2008) Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy. Immunogenetics 60:439–447

    Article  PubMed  CAS  Google Scholar 

  12. Chang CC, Ferrone S (2007) Immune selective pressure and HLA class I antigen defects in malignant lesions. Cancer Immunol Immunother 56(2):227–236

    Article  PubMed  CAS  Google Scholar 

  13. Bodmer WF (1987) The HLA system: structure and function. J Clin Pathol 40:948–958

    Article  PubMed  CAS  Google Scholar 

  14. Seliger B (2008) Different regulation of MHC class I antigen processing components in human tumors. J Immunotoxicol 5:361–367

    Article  PubMed  CAS  Google Scholar 

  15. Campoli M, Ferrone S (2008) HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. Oncogene 27:5869–5885

    Article  PubMed  CAS  Google Scholar 

  16. Ruiz-Cabello F, Nevot MA, Garrido F (1988) MHC class I and II gene expression on human tumors. Adv Exp Med Biol 233:119–128

    PubMed  CAS  Google Scholar 

  17. Seliger B, Stoehr R, Handke D, Mueller A, Ferrone S, Wullich B, Tannapfel A, Hofstaedter F, Hartmann A (2009) Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer. Cancer Immunol Immunother 59:529–540

    Article  PubMed  Google Scholar 

  18. Norell H, Carlsten M, Ohlum T, Malmberg KJ, Masucci G, Schedvins K, Altermann W, Handke D, Atkins D, Seliger B, Kiessling R (2006) Frequent loss of HLA-A2 expression in metastasizing ovarian carcinomas associated with genomic haplotype loss and HLA-A2-restricted HER-2/neu-specific immunity. Cancer Res 66:6387–6394

    Article  PubMed  CAS  Google Scholar 

  19. Ljunggren HG, Malmberg KJ (2007) Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol 7:329–339

    Article  PubMed  CAS  Google Scholar 

  20. Chan CJ, Andrews DM, Smyth MJ (2008) Can NK cells be a therapeutic target in human cancer? Eur J Immunol 38:2964–2968

    Article  PubMed  CAS  Google Scholar 

  21. Hallett WH, Ames E, Motarjemi M, Barao I, Shanker A, Tamang DL, Sayers TJ, Hudig D, Murphy WJ (2008) Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition. J Immunol 180:163–170

    PubMed  CAS  Google Scholar 

  22. Kruschinski A, Moosmann A, Poschke I, Norell H, Chmielewski M, Seliger B, Kiessling R, Blankenstein T, Abken H, Charo J (2008) Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas. Proc Natl Acad Sci U S A 105:17481–17486

    Article  PubMed  CAS  Google Scholar 

  23. Norell H, Poschke I, Charo J, Wei WZ, Erskine C, Piechocki MP, Knutson KL, Bergh J, Lidbrink E, Kiessling R (2010) Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial. J Transl Med 8:53

    Article  PubMed  Google Scholar 

  24. Triulzi C, Vertuani S, Curcio C, Antognoli A, Seibt J, Akusjarvi G, Wei WZ, Cavallo F, Kiessling R (2010) Antibody-dependent natural killer cell-mediated cytotoxicity engendered by a kinase-inactive human HER2 adenovirus-based vaccination mediates resistance to breast tumors. Cancer Res 70:7431–7441

    Article  PubMed  CAS  Google Scholar 

  25. Cozar JM, Canton J, Tallada M, Concha A, Cabrera T, Garrido F, Ruiz-Cabello Osuna F (2005) Analysis of NK cells and chemokine receptors in tumor infiltrating CD4 T lymphocytes in human renal carcinomas. Cancer Immunol Immunother 54:858–866

    Article  PubMed  CAS  Google Scholar 

  26. Meyerhuber P, Conrad H, Starck L, Leisegang M, Busch DH, Uckert W, Bernhard H (2010) Targeting the epidermal growth factor receptor (HER) family by T cell receptor gene-modified T lymphocytes. J Mol Med 88:1113–1121

    Article  PubMed  CAS  Google Scholar 

  27. Kraman M, Bambrough PJ, Arnold JN, Roberts EW, Magiera L, Jones JO, Gopinathan A, Tuveson DA, Fearon DT (2010) Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science 330:827–830

    Article  PubMed  CAS  Google Scholar 

  28. Magner WJ, Kazim AL, Stewart C, Romano MA, Catalano G, Grande C, Keiser N, Santaniello F, Tomasi TB (2000) Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors. J Immunol 165:7017–7024

    PubMed  CAS  Google Scholar 

  29. Khan AN, Gregorie CJ, Tomasi TB (2008) Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells. Cancer Immunol Immunother 57:647–654

    Article  PubMed  CAS  Google Scholar 

  30. Garrido C, Algarra I, Maleno I, Stefanski J, Collado A, Garrido F, Garcia-Lora AM (2009) Alterations of HLA class I expression in human melanoma xenografts in immunodeficient mice occur frequently and are associated with higher tumorigenicity. Cancer Immunol Immunother 59:13–26

    Article  PubMed  Google Scholar 

  31. Fratta E, Sigalotti L, Colizzi F, Covre A, Nicolay HJ, Danielli R, Fonsatti E, Altomonte M, Calabro L, Coral S, Maio M (2010) Epigenetically regulated clonal heritability of CTA expression profiles in human melanoma. J Cell Physiol 223:352–358

    PubMed  CAS  Google Scholar 

  32. Marks PA, Xu WS (2009) Histone deacetylase inhibitors: potential in cancer therapy. J Cell Biochem 107:600–608

    Article  PubMed  CAS  Google Scholar 

  33. Bhat SA, Czuczman (2009) Novel antibodies in the treatment of non-Hodgkin’s lymphoma. Neth J Med 67:311–321

    PubMed  CAS  Google Scholar 

  34. Huot R, Levy R (2009) Idiotype vaccination for lymphoma: moving towards optimisation. Leuk Lymphoma 50:1–2

    Article  Google Scholar 

  35. Timmerman JM, Vose JM, Czerwinski DK, Weng WK, Ingolia D, Mayo M, Denney DW, Levy R (2009) Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma. Leuk Lymphoma 50:37–46

    Article  PubMed  CAS  Google Scholar 

  36. Chen CG, Lu YT, Lin M, Savelyeva N, Stevenson FK, Zhu D (2009) Amplification of immune responses against a DNA-delivered idiotypic lymphoma antigen by fusion to the B subunit of E. coli heat labile toxin. Vaccine 27:4289–4296

    Article  PubMed  CAS  Google Scholar 

  37. Varghese B, Widman A, Do J, Taidi B, Czerwinski DK, Timmerman J, Levy S, Levy R (2009) Generation of CD8 + T cell-mediated immunity against idiotype-negative lymphoma escapees. Blood 114:4477–4485

    Article  PubMed  CAS  Google Scholar 

  38. Wierda WG, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, Robak T, Furman RR, Hillmen P, Trneny M, Dyer MJ, Padmanabhan S, Piotrowska M, Kozak T, Chan G, Davis R, Losic N, Wilms J, Russell CA, Osterborg A (2010) Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 28:1749–1755

    Article  PubMed  CAS  Google Scholar 

  39. Flowers CR, Armitage JO (2010) A decade of progress in lymphoma: advances and continuing challenges. Clin Lymphoma Myeloma Leuk 10:414–423

    Article  PubMed  Google Scholar 

  40. Keating GM (2010) Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. Drugs 70:1445–1476

    Article  PubMed  CAS  Google Scholar 

  41. Schaniel C, Gottar M, Roosnek E, Melchers F, Rolink AG (2002) Extensive in vivo self-renewal, long-term reconstitution capacity, and hematopoietic multipotency of Pax5-deficient precursor B-cell clones. Blood 99(8):2760–2766

    Article  PubMed  CAS  Google Scholar 

  42. Ikawa T, Hirose S, Masuda K, Kakugawa K, Satoh R, Shibano-Satoh A, Kominami R, Katsura Y, Kawamoto H (2010) An essential developmental checkpoint for production of the T cell lineage. Science 329:93–96

    Article  PubMed  CAS  Google Scholar 

  43. Kruser TJ, Wheeler DL (2010) Mechanisms of resistance to HER family targeting antibodies. Exp Cell Res 316:3639–3647

    Article  Google Scholar 

  44. Leth-Larsen R, Lund RR, Ditzel HJ (2010) Plasma membrane proteomics and its application in clinical cancer biomarker discovery. Mol Cell Proteomics 12:1369–1382

    Google Scholar 

  45. Hasegawa S, Furukawa Y, Li M, Satoh S, Kato T, Watanabe T, Katagiri T, Tsunoda T, Yamaoka Y, Nakamura Y (2002) Genome-wide analysis of gene expression in intestinal-type gastric cancers using a complementary DNA microarray representing 23, 040 genes. Cancer Res 62:7012–7017

    PubMed  CAS  Google Scholar 

  46. Esseghir S, Reis-Filho JS, Kennedy A, James M, O’Hare MJ, Jeffery R, Poulsom R, Isacke CM (2006) Identification of transmembrane proteins as potential prognostic markers and therapeutic targets in breast cancer by a screen for signal sequence encoding transcripts. J Pathol 210:420–430

    Article  PubMed  CAS  Google Scholar 

  47. Alsoe L, Stacy JE, Fossa A, Funderud S, Brekke OH, Gaudernack G (2008) Identification of prostate cancer antigens by automated high-throughput filter immunoscreening. J Immunol Methods 330:12–23

    Article  PubMed  CAS  Google Scholar 

  48. Nelson AL, Dhimolea E, Reichert JM (2010) Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 9:767–774

    Article  PubMed  CAS  Google Scholar 

  49. Chiang CL, Ledermann JA, Aitkens E, Benjamin E, Katz DR, Chain BM (2008) Oxidation of ovarian epithelial cancer cells by hypochlorous acid enhances immunogenicity and stimulates T cells that recognize autologous primary tumor. Clin Cancer Res 14:4898–4907

    Article  PubMed  CAS  Google Scholar 

  50. Disis ML, Wallace DR, Gooley TA, Dang Y, Slota M, Lu H, Coveler AL, Childs JS, Higgins DM, Fintak PA, dela Rosa C, Tietje K, Link J, Waisman J, Salazar LG (2009) Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. J Clin Oncol 27:4685–4692

    Article  PubMed  CAS  Google Scholar 

  51. Bhat R, Dempe S, Dinsart C, Rommelaere J (2011) Enhancement of NK cell anti-tumour responses using an oncolytic parvovirus. Int J Cancer 128:908–919

    Article  PubMed  CAS  Google Scholar 

  52. Pandha H, Melcher A, Harrington K, Vile R (2009) Oncolytic viruses: time to compare, contrast, and combine? Mol Ther 17:934–935

    Article  PubMed  CAS  Google Scholar 

  53. Natsume A, Kondo Y, Ito M, Motomura K, Wakabayashi T, Yoshida J (2010) Epigenetic aberrations and therapeutic implications in gliomas. Cancer Sci 101:1331–1336

    Article  PubMed  CAS  Google Scholar 

  54. Dhodapkar MV (2010) Immunity to stemness genes in human cancer. Curr Opin Immunol 22:245–250

    Article  PubMed  CAS  Google Scholar 

  55. Moore N, Lyle S (2010) Quiescent, slow-cycling stem cell populations in cancer: a review of the evidence and discussion of significance. J Oncol 2011–2022

  56. Jin L, Lee EM, Ramshaw HS, Busfield SJ, Peoppl AG, Wilkinson L, Guthridge MA, Thomas D, Barry EF, Boyd A, Gearing DP, Vairo G, Lopez AF, Dick JE, Lock RB (2009) Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell 5:31–42

    Article  PubMed  CAS  Google Scholar 

  57. Agarwala SS, Case S (2010) Everolimus (RAD001) in the treatment of advanced renal cell carcinoma: a review. Oncologist 15:236–245

    Article  PubMed  CAS  Google Scholar 

  58. Romero P, Cerottini JC, Speiser DE (2006) The human T cell response to melanoma antigens. Adv Immunol 92:187–224

    Article  PubMed  CAS  Google Scholar 

  59. Caballero OL, Zhao Q, Rimoldi D, Stevenson BJ, Svobodova S, Devalle S, Rohrig UF, Pagotto A, Michielin O, Speiser D, Wolchok JD, Liu C, Pejovic T, Odunsi K, Brasseur F, Van den Eynde BJ, Old LJ, Lu X, Cebon J, Strausberg RL, Simpson AJ (2010) Frequent MAGE mutations in human melanoma. PLoS One 5

  60. Beverley PC, Lowenthal RM, Tyrrell DA (1973) Immune responses in mice to tumour challenge after immunization with Newcastle disease virus-infected or x-irradiated tumour cells or cell fractions. Int J Cancer 11:212–223

    Article  PubMed  CAS  Google Scholar 

  61. Peggs KS, Quezada SA, Korman AJ, Allison JP (2006) Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol 18:206–213

    Article  PubMed  CAS  Google Scholar 

  62. Yamaguchi T, Sakaguchi S (2006) Regulatory T cells in immune surveillance and treatment of cancer. Semin Cancer Biol 16:115–123

    Article  PubMed  CAS  Google Scholar 

  63. Kortylewski M, Swiderski P, Herrmann A, Wang L, Kowolik C, Kujawski M, Lee H, Scuto A, Liu Y, Yang C, Deng J, Soifer HS, Raubitschek A, Forman S, Rossi JJ, Pardoll DM, Jove R, Yu H (2009) In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat Biotechnol 27:925–932

    Article  PubMed  CAS  Google Scholar 

  64. Groh V, Li YQ, Cioca D, Hunder NN, Wang W, Riddell SR, Yee C, Spies T (2005) Efficient cross-priming of tumor antigen-specific T cells by dendritic cells sensitized with diverse anti-MICA opsonized tumor cells. Proc Natl Acad Sci U S A 102:6461–6466

    Article  PubMed  CAS  Google Scholar 

  65. Sancho D, Mourao-Sa D, Joffre OP, Schulz O, Rogers NC, Pennington DJ, Carlyle JR, Reis e Sousa C (2008) Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin. J Clin Invest 118:2098

    Article  PubMed  CAS  Google Scholar 

  66. Arce F, Rowe HM, Chain B, Lopes L, Collins MK (2009) Lentiviral vectors transduce proliferating dendritic cell precursors leading to persistent antigen presentation and immunization. Mol Ther 17:1643–1650

    Article  PubMed  CAS  Google Scholar 

  67. Xue SA, Gao L, Thomas S, Hart DP, Xue JZ, Gillmore R, Voss RH, Morris E, Stauss HJ (2009) Development of a Wilms’ tumor antigen-specific T-cell receptor for clinical trials: engineered patient’s T cells can eliminate autologous leukemia blasts in NOD/SCID mice. Haematologica 95:126–134

    Article  PubMed  Google Scholar 

  68. Stevenson FK, Ottensmeier CH, Rice J (2010) DNA vaccines against cancer come of age. Curr Opin Immunol 22:264–270

    Article  PubMed  CAS  Google Scholar 

  69. Theurillat JP, Ingold F, Frei C, Zippelius A, Varga Z, Seifert B, Chen YT, Jager D, Knuth A, Moch H (2007) NY-ESO-1 protein expression in primary breast carcinoma and metastases: correlation with CD8 + T-cell and CD79a + plasmacytic/B-cell infiltration. Int J Cancer 120:2411–2417

    Article  PubMed  CAS  Google Scholar 

  70. Knights AJ, Nuber N, Thomson CW, de la Rosa O, Jager E, Tiercy JM, van den Broek M, Pascolo S, Knuth A, Zippelius A (2009) Modified tumour antigen-encoding mRNA facilitates the analysis of naturally occurring and vaccine-induced CD4 and CD8 T cells in cancer patients. Cancer Immunol Immunother 58:325–338

    Article  PubMed  CAS  Google Scholar 

  71. Kim PS, Armstrong TD, Song H, Wolpoe ME, Weiss V, Manning EA, Huang LQ, Murata S, Sgouros G, Emens LA, Reilly RT, Jaffee EM (2008) Antibody association with HER-2/neu-targeted vaccine enhances CD8 T cell responses in mice through Fc-mediated activation of DCs. J Clin Invest 118:1700–1711

    Article  PubMed  CAS  Google Scholar 

  72. Topalian SL, Rosenberg SA (1987) Therapy of cancer using the adoptive transfer of activated killer cells and interleukin-2. Acta Haematol 78(Suppl 1):75–76

    Google Scholar 

  73. Dudley ME, Rosenberg SA (2003) Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 3:666–675

    Article  PubMed  CAS  Google Scholar 

  74. Morgan RA, Dudley ME, Rosenberg SA (2010) Adoptive cell therapy: genetic modification to redirect effector cell specificity. Cancer J 16:336–341

    Article  PubMed  CAS  Google Scholar 

  75. Frankenberger B, Regn S, Geiger C, Noessner E, Falk CS, Pohla H, Javorovic M, Silberzahn T, Wilde S, Buchner A, Siebels M, Oberneder R, Willimsky G, Pezzutto A, Blankenstein T, Schendel DJ (2005) Cell-based vaccines for renal cell carcinoma: genetically-engineered tumor cells and monocyte-derived dendritic cells. World J Urol 23:166–174

    Article  PubMed  CAS  Google Scholar 

  76. Schendel DJ (2007) Dendritic cell vaccine strategies for renal cell carcinoma. Expert Opin Biol Ther 7:221–232

    Article  PubMed  CAS  Google Scholar 

  77. Spranger S, Javorovic M, Burdek M, Wilde S, Mosetter B, Tippmer S, Bigalke I, Geiger C, Schendel DJ, Frankenberger B (2010) Generation of Th1-polarizing dendritic cells using the TLR7/8 agonist CL075. J Immunol 185:738–747

    Article  PubMed  CAS  Google Scholar 

  78. Buchner A, Pohla H, Willimsky G, Frankenberger B, Frank R, Baur-Melnyk A, Siebels M, Stief CG, Hofstetter A, Kopp J, Pezzutto A, Blankenstein T, Oberneder R, Schendel DJ (2010) Phase 1 trial of allogeneic gene-modified tumor cell vaccine RCC-26/CD80/IL-2 in patients with metastatic renal cell carcinoma. Hum Gene Ther 21:285–297

    Article  PubMed  CAS  Google Scholar 

  79. Palmer DC, Chan CC, Gattinoni L, Wrzesinski C, Paulos CM, Hinrichs CS, Powell DJ Jr, Klebanoff CA, Finkelstein SE, Fariss RN, Yu Z, Nussenblatt RB, Rosenberg SA, Restifo NP (2008) Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity. Proc Natl Acad Sci U S A 105:8061–8066

    Article  PubMed  CAS  Google Scholar 

  80. Klebanoff CA, Yu Z, Hwang LN, Palmer DC, Gattinoni L, Restifo NP (2009) Programming tumor-reactive effector memory CD8 + T cells in vitro obviates the requirement for in vivo vaccination. Blood 114:1776–1783. doi:10.1182/blood-2008-12-192419

    Article  PubMed  CAS  Google Scholar 

  81. Lu C, Williams AK, Chalasani V, Martinez CH, Chin J (2010) Immunotherapy for metastatic prostate cancer: where are we at with sipuleucel-T? Expert Opin Biol Ther 11:99–108. 82

    Google Scholar 

  82. Ruttinger D, Winter H, van den Engel NK, Hatz R, Jauch KW, Fox BA, Weber JS (2010) Immunotherapy of cancer: key findings and commentary on the third Tegernsee conference. Oncologist 15:112–118

    Article  PubMed  Google Scholar 

  83. Hamid O, Solomon JC, Scotland R, Garcia M, Sian S, Ye W, Groshen SL, Weber JS (2007) Alum with interleukin-12 augments immunity to a melanoma peptide vaccine: correlation with time to relapse in patients with resected high-risk disease. Clin Cancer Res 13:215–222

    Article  PubMed  CAS  Google Scholar 

  84. O’Day SJ, Atkins MB, Boasberg P, Wang HJ, Thompson JA, Anderson CM, Gonzalez R, Lutzky J, Amatruda T, Hersh EM, Weber JS (2009) Phase II multicenter trial of maintenance biotherapy after induction concurrent biochemotherapy for patients with metastatic melanoma. J Clin Oncol 27:6207–6212

    Article  PubMed  Google Scholar 

  85. Hersh EM, O’Day SJ, Powderly J, Khan KD, Pavlick AC, Cranmer LD, Samlowski WE, Nichol GM, Yellin MJ, Weber JS (2010) A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma. Invest New Drugs. Ref details not available

  86. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbe C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723

    Article  PubMed  CAS  Google Scholar 

  87. Ribas A, Comin-Anduix B, Chmielowski B, Jalil J, de la Rocha P, McCannel TA, Ochoa MT, Seja E, Villanueva A, Oseguera DK, Straatsma BR, Cochran AJ, Glaspy JA, Hui L, Marincola FM, Wang E, Economou JS, Gomez-Navarro J (2009) Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res 15:6267–6276

    Article  PubMed  CAS  Google Scholar 

  88. von Euw E, Chodon T, Attar N, Jalil J, Koya RC, Comin-Anduix B, Ribas A (2009) CTLA4 blockade increases Th17 cells in patients with metastatic melanoma. J Transl Med 7:35

    Article  Google Scholar 

  89. Cohen AD, Schaer DA, Liu C, Li Y, Hirschhorn-Cymmerman D, Kim SC, Diab A, Rizzuto G, Duan F, Perales MA, Merghoub T, Houghton AN, Wolchok JD (2010) Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation. PLoS One 5:e10436

    Article  PubMed  Google Scholar 

  90. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, Gilson MM, Wang C, Selby M, Taube JM, Anders R, Chen L, Korman AJ, Pardoll DM, Lowy I, Topalian SL (2010) Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28:3167–3175

    Article  PubMed  CAS  Google Scholar 

  91. Wang W, Lau R, Yu D, Zhu W, Korman A, Weber J (2009) PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4 + CD25(Hi) regulatory T cells. Int Immunol 21:1065–1077

    Article  PubMed  CAS  Google Scholar 

  92. Breckpot K, Heirman C, De Greef C, van der Bruggen P, Thielemans K (2004) Identification of new antigenic peptide presented by HLA-Cw7 and encoded by several MAGE genes using dendritic cells transduced with lentiviruses. J Immunol 172:2232–2237

    PubMed  CAS  Google Scholar 

  93. Maslak PG, Dao T, Krug LM, Chanel S, Korontsvit T, Zakhaleva V, Zhang R, Wolchok JD, Yuan J, Pinilla-Ibarz J, Berman E, Weiss M, Jurcic J, Frattini MG, Scheinberg DA (2010) Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. Blood 116:171–179

    Article  PubMed  CAS  Google Scholar 

  94. Weden S, Klemp M, Gladhaug IP, Moller M, Eriksen JA, Gaudernack G, Buanes T (2010) Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras. Int J Cancer 128:1120–1128

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Tumoral Biology, Centre for Molecular Immunology, Habana, Cuba

    Yeranddy A. Alpizar

  2. Division of Infection and Immunity, University College London (UCL), London, UK

    Benjamin Chain, Mary K. Collins & David Katz

  3. UCL Institute of Ophthalmology, 11-43 Bath Street, London, EC1V 9EL, UK

    John Greenwood, Hans J. Stauss & N. Avrion Mitchison

Authors
  1. Yeranddy A. Alpizar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Benjamin Chain
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mary K. Collins
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. John Greenwood
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. David Katz
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hans J. Stauss
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. N. Avrion Mitchison
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to N. Avrion Mitchison.

Additional information

This paper is a Focussed Research Review based on a presentation given at the Tenth International Conference on Progress in Vaccination against Cancer (PIVAC 10), held in St. Catharine’s College, Cambridge, UK, 27–30th September 2010. It is part of a CII series of Focussed Research Reviews and meeting report.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Alpizar, Y.A., Chain, B., Collins, M.K. et al. Ten years of progress in vaccination against cancer: the need to counteract cancer evasion by dual targeting in future therapies. Cancer Immunol Immunother 60, 1127–1135 (2011). https://doi.org/10.1007/s00262-011-0985-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-011-0985-7

Keywords

Search

Navigation